Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Top EstimatesZacks Investment Research • 05/06/20
Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138GlobeNewsWire • 04/21/20
Jazz Pharma's Mixed Earnings, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 02/28/20
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHDGlobeNewsWire • 01/21/20
Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD PatientsGlobeNewsWire • 12/09/19
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag EstimatesZacks Investment Research • 11/05/19
Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 10/29/19